Abstract
Understanding broadly neutralizing antibody (bnAb) lineage development in rhesus macaques (RMs) infected with simian-human immunodeficiency virus (SHIV) may inform human immunodeficiency virus (HIV)-1 vaccine designs. We analyzed HIV-1 envelope (Env)-antibody coevolution in 18 RMs infected with SHIV.BG505 (subtype A) and found conserved patterns of antibody recognition and Env escape, including in three animals that developed V3-glycan-reactive bnAbs. From one RM with V3-glycan targeted plasma Abs that neutralized heterologous HIV-1 strains, we isolated 203 members of a single clonal antibody lineage designated DH1030. DH1030 antibodies demonstrated genetic, functional, and structural similarities with the human V3-glycan bnAb lineage DH270, which was isolated from an individual with subtype C HIV-1 CH848 infection. Human-DH270 and macaque-DH1030 bnAbs shared early improbable mutations in the heavy chain complementarity determining region 2 (HCDR2) that were critical for bnAb development. These convergent patterns of antibody evolution, accumulation of key improbable mutations, and mode of epitope recognition were shared across primate species and distinct HIV-1 subtypes, findings that may be leveraged in HIV-1 vaccine designs Furthermore, our data highlight the value of SHIV-infected macaques as an outbred model system to explore conserved molecular pathways of bnAb development following infection and vaccination.
Editor’s Summary:
Characterizing Convergence. Despite their use in vaccine and immunotherapeutic research, animal models do not always faithfully recapitulate the immune response observed in humans, in part due to species-level differences in immunogenetics. Thus, a clear understanding of how well species such as rhesus macaques model the immune responses of humans is essential. Here, Clark et al. asked if rhesus macaques infected with a simian-human immunodeficiency virus developed antibodies that looked like what has been observed in people living with HIV. The authors found that the macaques could develop antibodies targeting the V3-glycan of the HIV envelope protein, and that these antibodies had genetic, functional, and structural similarities to the human V3-glycan broadly neutralizing antibody, DH270. These findings highlight the value of research in rhesus macaques, especially for vaccines and Immunotherapeutics that target V3-glycan broadly neutralizing antibodies. –Courtney Malo
ONE SENTENCE SUMMARY:
Broadly neutralizing antibodies targeting the HIV-1 envelope surface protein develop via a common maturation pathway in humans and macaques.
Introduction
Despite the advent of pre-exposure prophylaxis for human immunodeficiency virus-type 1 (HIV-1)-seronegative individuals, and antiretroviral therapy for people living with HIV-1, people are still becoming infected and dying from HIV-1–related causes globally. Thus, we still need vaccines in the fight against HIV-1, and a major goal of a preventive vaccine against HIV-1 is the induction of broadly neutralizing antibodies (bnAbs) that target conserved regions on the envelope (Env) surface protein HIV-1 vaccines BnAbs targeting the V3-glycan epitope supersite on HIV-1 Env use different immunogenetics and structural angles of approach for antigen recognition (1). Moreover, potent V3-glycan bnAbs have been isolated from people living HIV-1 (2, 3) and from SHIV-infected monkeys (4–6). Thus, V3-glycan bnAbs are a desired target for HIV-1 vaccines.
We previously isolated a V3-glycan bnAb lineage termed DH270 from an individual (CH848) with chronic HIV-1 infection (7). DH270 lineage progression from the unmutated common ancestor (UCA) and intermediate antibody (IA) to mature antibodies (Abs) was associated with the acquisition of an arginine residue at position 57 (R57) in the heavy chain complementarity determining region-2 (HCDR2) that displaced the Env V1 loop while accessing the GDIR motif in the V3-glycan supersite (8, 9). The emergence of R57 was a result of a key improbable mutation (G57R) associated with DH270 neutralization breadth (8). Moreover, Ab-Env co-evolution studies in CH848 identified an autologous Env with V1 glycan deletions that was postulated to have primed the DH270 lineage (9); subsequent immunogens based on this design successfully expanded DH270 lineage B cells in mouse models (9, 10). Additionally, previous studies have reported HIV-1 Envs with V1 glycan deletions as candidate immunogens for eliciting V3-glycan-like B cells in animal models (4, 11, 12). More recently, RMs infected with pathogenic SHIVs (13) were shown to induce HIV-1 Env bnAbs and recapitulated Env-Ab co-evolution events, including Env mutations that select for bnAb lineage induction, expansion and affinity maturation (4, 5). Thus, this macaque model of bnAb induction provides a molecular guide for bnAb induction via vaccination by employing similar Ab-Env coevolution studies as those observed in human HIV-1 infection (7).
Germinal centers (GC) play a critical role in development of antigen-reactive B cell responses (14). Antigen-activated GC precursor B cells establish the dark zone in which they undergo rounds of proliferation and somatic hypermutation (SHM), followed by migration to the light zone for positive selection as plasmablasts, memory precursor B cells, or undergo dark zone recirculation for further SHM (15, 16). However, the cellular mechanisms of bnAb development in macaque GCs, including the dynamics of bnAb B cells in GC dark and light zones during lineage maturation, remain poorly defined.
In this study, human and macaque V3-glycan bnAbs were elicited by different Envs (subtype A BG505 in rhesus macaque; subtype C CH848 in human). For the SHIV.BG505 infected macaques, we identified a subset of viruses containing deletions in V1 that circulated coincident with priming of the DH1030 bnAb lineage, similar to the scenario postulated for DH270 priming (7, 9) and for SHIV.5MUT induced bnAbs (4). We then identified an early shared key functional improbable mutation in the HCDR2 of both rhesus macaque and human bnAb lineages that conferred similar Ab structure and epitope recognition. To investigate how two divergent HIV-1 Envs infecting two different primate species could share common developmental pathways, we analyzed the maturation pathway of the macaque V3-glycan bnAb lineage by performing B cell receptor (BCR) and transcriptome sequencing of B cell compartments in peripheral blood cells (PBMCs) and secondary lymphoid tissues, including lymph node (LN), spleen, and bone marrow (BM).
Results
Patterns of Env-Ab coevolution converged in SHIV.BG505 infected RMs.
We inoculated 18 RMs with SHIV.BG505 in this study (Table 1). Fourteen RMs were inoculated with SHIV.BG505 bearing a potential N-linked glycosylation site (PNGS) at Env position 332 (SHIV.BG505.N332), two RMs with SHIV.BG505 lacking a PNGS at Env position 332 (SHIV.BG505.T332), and two RMs with a 50:50 mixture of these SHIVs. All animals became productively infected with peak plasma virus titers at day 14 of 106-108 vRNA molecules/ml (Fig. 1A). Plasma viral load setpoints at week 12 ranged from 102-105 vRNA molecules/ml. Two monkeys died of rapid disease progression to AIDS within the first six months of infection. Except for RM6447, which died of AIDS-like illness at week 9 post-infection, all monkeys developed autologous strain-specific neutralizing antibody (nAb) half-maximal inhibitory dilution (ID50) titers between 1:40 – 1:10,000 (Fig. 1A). We defined neutralization breadth as ID50 titers of at least 1:20 against 4 or more heterologous viruses in a test panel of 16 tier-2 or difficult-to-neutralize strains. At 48 weeks post-SHIV infection, none of 15 SHIV-BG505-infected RMs tested exhibited neutralization breadth reaching this threshold (data file S1). Between weeks 56 and 96, three RMs, 08N021, 10N011 and 6923, reached this threshold, eventually neutralizing 31–88% of the test panel (Fig. 1B; data file S1). We mapped plasma neutralization breadth for the three monkeys, 08N021, 10N011 and 6923, to the canonical V3-glycan bnAb epitope motifs N332 and 324GDIR327 in heterologous Env backbones (Fig. 1C). Thus, 3 of 18 monkeys infected by SHIV.BG505 developed V3-glycan bnAbs, but only after more than one year of SHIV infection.
Table 1.
RMs infected with allelic variants of SHIV BG505 designed to replicate efficiently in Indian rhesus macaques and to induce N332 targeted antibodies.
| Animal ID | Inoculum | Number of variants | Stock derivation | Dosage P27 ng/variant | Route | CD8 Depletion | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Residue 332 | Residue 375 | ||||||
|
| |||||||
| 6434* | N | S, M, H, Y, F, W | 6 | 293T cell line | 50 | IV | No |
| 6442* | N | S, M, H, Y, F, W | 6 | 293T cell line | 50 | IV | No |
| 6446* | T | S, M, H, Y, F, W | 6 | 293T cell line | 50 | IV | No |
| 6447* | T | S, M, H, Y, F, W | 6 | 293T cell line | 50 | IV | No |
| 6454* | N & T | S, M, H, Y, F, W | 12 | 293T cell line | 50 | IV | No |
| 43335* | N & T | S, M, H, Y, F, W | 12 | 293T cell line | 50 | IV | No |
|
| |||||||
| 42591 | N | Y | 1 | Rh CD4+ T cells | 50 | IV | Yes |
| 6923 | N | Y | 1 | Rh CD4+ T cells | 50 | IV | Yes |
| 6924 | N | Y | 1 | Rh CD4+ T cells | 50 | IV | Yes |
|
| |||||||
| 6715 | N | Y | 1 | RhCD4+ T cells | 8 | IR | No |
| 6717 | N | Y | 1 | Rh CD4+ T cells | 1 | IR | No |
| 6718 | N | Y | 1 | Rh CD4+ T cells | 8 | IR | No |
| 6719 | N | Y | 1 | Rh CD4+ T cells | 8 | IR | No |
| 6706 | N | Y | 1 | Rh CD4+ T cells | 1.5 | IR | No |
| 6708 | N | Y | 1 | Rh CD4+ T cells | 1.5 | IR | No |
| T283 | N | Y | 1 | Rh CD4+ T cells | 1.5 | IR | No |
| 08N021 | N | Y | 1 | Rh CD4+ T cells | 1 | IR | No |
| 10N011 | N | Y | 1 | Rh CD4+ T cells | 1 | IR | No |
Asterisk (*) indicates data adapted from (13). Abbreviations: IR, intrarectal; IV, intravaginal; Rh, rhesus; and residues N (asparagine), Y (tyrosine), S (Serine), H (histidine), F (phenylalanine) and W (tryptophan).
Figure 1. Varied viral load kinetics and neutralizing antibody responses were observed in SHIV-BG505-infected RMs.

(A) Longitudinal viral loads (upper panel) and autologous nAb titers (lower panel) are shown for each animal. The dashed line in the upper panel indicates the limit of quantification (LOQ) for viral RNA (250 copies/ml). Animals that progressed to AIDS are marked with a red cross (†). The lower panel depicts the reciprocal plasma ID50 titers against the autologous virus. Animals are grouped by inoculation route: intravenous (left), intrarectal (middle), and intravenous with anti-CD8 treatment (right). Symbols denote infection with SHIV-BG505 containing 332N (solid), 332T (open dark green), or mixed variants (open orange). Detailed infection data are in Table 1. (B) Plasma from 12 of 18 animals that developed persistent autologous nAb responses was tested against a panel of 16 heterologous tier-2 viruses. Initial screening used samples from approximately one-year post-infection; for animals exhibiting broad neutralizing activity, earlier time points were tested to identify onset. Gray shaded region indicates area below limit of detection at 20 ID50 (dotted line). (C) Mapping of the plasma neutralizing response against mutants lacking key V3-glycan epitope residues in different heterologous backbones. The Y-axes represent reciprocal of ID50 titers against the indicated mutant viruses. Data shown in (A to C) were generated from individual experiments with technical replicates.
Because BG505 is a prototypic strain used widely in HIV-1 vaccine research, we sought to understand the molecular basis for its early strain-specific immunogenicity (17) and how the Env evolved to elicit bnAbs. The viral quasi-species in plasma is a sensitive and dynamic measure of viral fitness and selection pressures, including those exerted by nAbs, cytotoxic T cells and antiretroviral drugs (18–20). Single genome sequencing (SGS) provides a proportional representation of viral sequences in plasma and maintains sequence linkage across complete env genes, thereby enabling sites of Ab recognition to be mapped across Env (21). We thus compared the patterns of Env sequence evolution in 17 of 18 macaques where samples were available and vRNA titers were sufficient to identify signature sites of recognition and escape from autologous strain-specific antibodies and bnAbs targeting the canonical V3-glycan epitope (fig. S1A and B). We first visualized Env gp140 sequence evolution over the course of infection in 17 monkeys compared with the person living with HIV, BG505 (fig. S1A). We used LASSIE (22) to detect Env sites under selection based on loss of transmitted-founder (TF) sequence in longitudinal SGS sequences and found evidence of positive selection across all infected monkeys and the human (Fig. 2A and B, fig. S2 to fig. S4). As seen previously for macaques infected with SHIVs bearing the same TF Env isolated from a human participant (5), there was remarkable convergence in Env evolution with the same or similar amino acid mutations identified under selection across the macaque hosts and the human (Fig. 2A to C). Of the 84 total LASSIE selected sites across the human subject BG505 and 17 RMs, 36 (43%) were selected in at least 2 human/rhesus hosts (fig. S4). These mutations also included recurrent glycan acquisition or deletion mutations that shaped the glycan shield evolution, such as the addition of glycans at sites 241 and 289, which cover an immunodominant “glycan hole” epitope (23), Additionally, early glycan addition at position 332 was observed in humans infected with wild-type BG505 (332T), in RM6446 infected with wild-type SHIV BG505 (332T), and in RM6454 and RM43335 infected with a SHIV BG505 332N and 332T mixture (fig S1A, S4A and S4B). When mapped on the trimer structure (Fig. 2C), the most recurrently selected sites fell in regions of the 241–289 glycan hole, the C3-V4 and V3 regions, in agreement with the presence of strain-specific mAbs in SHIV BG505-infected RMs (17). Six Env sites were selected in 11–13 hosts out of 17 RMs and the BG505 human; each of these sites was selected in BG505. Three such sites (347, 356, 358) were in the C3 region, two in the N241-N289 glycan hole (241 and 289) and one at the tip of V3 (R308H) that was selected for in 12 out of 17 RMs. The two RMs with plasma Abs that can neutralize multiclade heterologous HIV-1 strains (plasma breadth), RM08N021 and RM10N011, showed the highest overlap with selected Env sites in BG505 (7 and 9, respectively, out of 13 sites in BG505) (Fig. 2A to C). Although hypervariable loops evolve rapidly by mutations and indels even in within-host longitudinal Envs, we found several patterns of common indels shared across multiple RMs (fig. S4), including a 4-amino acid (aa) deletion in V1 loop.
Figure 2. HIV-1 Envs evolved over time in conjunction with autologous neutralization escape.

(A) Pixel plots depict amino acid changes in gp140 sequences obtained by SGS of plasma viral RNA from human BG505 and SHIV.BG505.332N infected RMs 08N021 and 10N011. Magenta arrows mark positions where the TF residue is lost in >80% of sequences at any time point. The V3-glycan bnAb epitope is boxed in blue. (B) Longitudinal sequences from (A) underwent LASSIE analysis using the human BG505.TF virus as reference. Sites with >80% TF loss (LASSIE sites) are magenta-labeled. Sequence logos show mutation frequencies over time, with TF residues blanked. PNGS sites are marked as an “O” in the alignments. Blue box indicates the V3-glycan bnAb epitope region, as in (A). (C) Common PNGS evolution patterns across human and macaque hosts are summarized. Predicted glycan shields are shown for SHIV BG505 TF (top left) and for longitudinal time points of wk117 for BG505 (top right), wk40 for RM10N011 (bottom left) and wk56 for RM08N021 (bottom right). For each longitudinal sample, glycan sites in 50% or more sequences from that sample were used. Blue sites on the structure indicate glycan sites, green the predicted glycan shield and magenta/pink show glycan holes that are otherwise conserved in M-group Envs. See also fig. S4B. (D) Structural mapping of Env sites under selection across ≥2 hosts from SHIV-BG505-infected macaques (n=17) as shown in fig. S4A. Sites selected in ≥2 hosts are mapped on the BG505 SOSIP.664 trimer (PDB: 5FYL); spheres are color-coded by number of hosts. (E) Plasma from weeks 24–104 was tested against parental BG505.T332N and its isogenic mutants in a single experiment to identify sites that are under positive selection. Fold reduction in ID50 titers (parental/mutant) quantifies escape: >3(red) = strong, 2–3 (yellow) = moderate, <2 (gray) = no change.
For many positively selected residues in gp140 in the first year of infection, we could phenotypically map an autologous, strain-specific nAb response (fig. S1B), including the previously characterized N241+N289 glycan hole and C3-V4-V5 epitopes from animal immunizations with BG505 Env trimer (23). In two of the three RMs with V3-glycan bnAbs (08N021 and 10N011), we assessed plasma neutralization at multiple time points spanning weeks 24 to 104. Given that SGS analysis revealed strong selection in the V3-glycan and 324GDIR327 region in these two animals (Fig. 2A to B, fig. S5), we expanded our mutant panel to include additional V3 mutations (N301A, D325N, H330Q, and N332T), along with a subset of mutants exhibiting pan-resistance (fig. S1B). Autologous nAbs developed in sequential waves. The initial response in both animals targeted the 241/289 glycan hole exclusively. As this wave subsided, nAbs targeting the C3/V4/V5 epitope emerged and became dominant, followed by their decline and the subsequent detection of bnAbs targeting V3-glycan epitopes (data file S1. Fig. 1C). BG505 Env variants in the human and the macaques that developed V3-glycan bnAbs evolved with common glycan shield patterns shaped by nAb selection pressure (Fig. 2C). Positively selected sites of mutation across all infected RMs are depicted on a surface projection of the trimer (Fig. 2D); the neutralization phenotype of these mutations mapped to different Env sites (Fig. 2E, fig. S1B). In the current study, we sought to isolate and characterize the V3-glycan bnAbs present in RM08N021 to elucidate their biophysical properties and ontogeny.
A V3-glycan bnAb lineage was isolated from RM08N021.
From RM08N021, we isolated four PBMC-derived members of a V3-glycan bnAb lineage (DH1030.1, DH1030.2, DH1030.3, and DH1030.4) using an antigen-specific B cell sort approach (24). We isolated two additional members of this lineage, DH1030.5 and DH1030.6, from bone marrow aspirate (BMA)-derived mononuclear cells using an antigen-unbiased plasmablast and plasma cell sort strategy (25). We found that DH1030.1-DH1030.5 encoded an improbable mutation from glycine to arginine at position 56 (G56R) in the HCDR2 similar to previously identified G57R functional improbable mutation in the human DH270 V3-glycan bnAb lineage (fig. S6A) (7). Moreover, this mutation was also critical for heterologous HIV-1 neutralization capacity of DH1030.1 when expressed as a recombinant mAb (fig. S6B) as similarly described for DH270 V3-glycan bnAb lineage development (7). Structural analyses of human V3-glycan bnAbs in complex with HIV-1 Envs (fig. S6C) indicated a role for a suitably positioned arginine in Ab heavy and light chain variable regions in mediating contact with the 324GDIR327 motif in Env. This was supported by site directed mutagenesis studies for human DH270 (7) and macaque DH1030 V3-glycan bnAbs (fig. S6B).
To visualize details of the Env epitope recognized by DH1030.1, we determined two cryo-EM structures of the DH1030.1 antigen binding fragment (Fab) bound to BG505 SOSIP or CH848 SOSIP. The cryo-EM maps showed three DH1030.1 Fab molecules bound symmetrically per Env trimer. Applying 3-fold symmetry resulted in a 3.5 Å resolution map for the BG505-DH1030.1 complex and a 3.7 Å resolution map for the CH848-DH1030.1 complex (Fig. 3A, fig. S7 and S8; tables S1 and S2). We determined the x-ray crystal structure of the DH1030.1 Fab at (1.79 Å resolution) (table S1). DH1030.1 bound at the Env V3-glycan supersite, burying a total of 1207 A2 and 1327 A2 at its interface with Env for the CH848-bound and BG505-bound complexes, respectively, and making contacts with protein surfaces and glycans, including the N332 glycan (Fig. 3B and C; table S3). The light chain DH1030.1 contacts with Env were limited to glycans, with R51, Y54, S61 making contact with the N332 glycan. We found that the conformations of the CDR loops in the free Fab were overall similar to the CDR conformations of the DH1030.1 Fab bound to Env, with a maximum ~2.4 Å Cα shift of the HCDR3 region spanning residues 101–109 being sufficient to accommodate binding to Env (fig. S9). The 17-aa residue long DH1030.1 HCDR3 loop extended into the binding site to contact protein residues Ile322, Gly324, Asp325, Arg327 and Gln328 in the V3 loop, while the Env N332 glycan stacked against the extended DH1030.1 HCDR3 loop (Fig. 3D).
Figure 3. Cryo-EM structures of DH1030.1 complexes revealed V3-glycan binding mode.

(A) CryoEM map of DH1030.1 Fab in complex with BG505.T332N SOSIP and CH848 10.17 DS.SOSIP_DT at high resolutions of 3.5 Å and 3.7 Å C3 symmetry, respectively. (B) The V1 loop (red) adopts a similar orientation as observed for the complex between DH270.6 (colored in wheat) and CH848 Env, contrasting with the orientation of the V1 loop observed in the complex with DH270-UCA (gray). (C and D) Atomic visualization of Env N332 glycan (C) and GDIR (D) interactions by DH1030.1; the HCDR3 loop makes extensive contacts with N332 glycan and the HCDR2 G56R mutation contacts the Env V3 GDIR motif. (E) PGT121 (dark green, PDB:5CEZ), 1010–74 (wheat, PDB:5T3Z) and DH270.6 (dark blue) (shown as surfaces) bnAbs make extensive contacts with N332 glycan (shown as sticks), as seen for DH1030.1. (F) Surface representation of DH270.6 and DH1030.1 bound to CH848 Env (cyan cartoon). Spheres represent the centers of mass (CM) of CH848 gp120 (red); the DH1030.1 heavy chain (HC, magenta), light chain (LC, yellow), and Fab (light green); and the DH270.6 HC (purple), LC (orange), and Fab (dark green). A 21.7° rotation of the LCs is observed in the binding angle of DH270.6 and DH1030.1 to CH848 Env. CryoEM structures with PDB IDs 6UM6 and 6UM5 were used as models for DH270.6 and DH270 UCA, respectively.
When compared to DH270 V3-glycan bnAb isolated from human HIV-1 infection (7, 9), we found that DH1030.1 shared similar binding footprint (Fig. 3E), consistent with the similarity in the evolution of a glycine to arginine mutation at an almost identical HCDR2 site in the human DH270 and macaque DH1030 V3-glycan bnAbs (Fig. 3F, fig. S6A). DH1030 mAbs bearing a revertant mutation at position 56 (R56G) in the HCDR2 of the heavy chain variable region (VH) had dramatic reduction or abrogation of HIV-1 neutralization against a panel of heterologous viruses (fig. S6B), indicating the emergence of VH G56R as a key mutation associated with acquisition of DH1030 heterologous HIV-1 neutralization capacity as previously described for human DH270 V3-glycan bnAb where VH G57R was associated with acquisition of neutralization breath (7). DH1030.1 and DH270.6 bound Env with overlapping footprints, although an ~22° rotation of the Fab oriented the DH1030.1 light chain away from Env, resulting in a heavy chain dominated recognition mode of DH1030.1, in contrast to DH270.6, where both heavy and light chains make extensive contacts with Env (Fig. 3F).
DH1030 mAbs neutralized up to 29% of a panel of 208 HIV-1 isolates, and up to 42% of 146 heterologous HIV-1 isolates bearing the N332 glycan in the 208-virus panel (Fig. 4A). Like DH270, DH1030 mAbs did not neutralize any of the 46 heterologous HIV-1 strains among the 208-virus panel that had N334 instead of N332 or did not encode either residue (Fig. 4B). Testing the statistical similarity of neutralization profiles between DH1030.5 and other human V3-glycan bnAbs (Fig. 4C), the highest similarity was found with DH270.1 with Pearson r2 = 0.22 between half-maximal inhibitory concentration (IC50) titers (P=0.0002) and 84% overlap in mutually sensitive or mutually resistant (Fisher’s exact test, P=3.1×10−25).
Figure 4. DH1030 V3-glycan bnAbs demonstrated neutralization breadth and potencies against heterologous HIV-1 strains.

(A and B) Neutralization titers of representative DH1030 Abs and known human V3-glycan bnAbs against a panel of 208 heterologous HIV-1 strains that encoded N332-glycan (A) or that encoded N334-glycan instead of N332 or encoded neither N332 nor N334 (B) in a single experiment. Abs are shown in columns and viruses in rows. Reference bnAbs 10–1074 and PGT128 were used for comparison. Neutralization was measured in TZM-bl cells and reported as IC50 values (μg/ml). Neutralization titer is color coded for potency. (A to B) Key for neutralization titers (IC50, μg/ml): <0.1 (red fill), 0.1 to <1 (orange), 1 to <10 (light green), 10 to 50 (dark green), and >50 (gray). (C) The left panels in each row show IC50 titers for DH1030.5 and other V3-glycan bnAbs for heterologous viruses from the 208-virus panel. Correlation coefficients and P values were calculated using Pearson and Kendall tau rank tests, and the linear regression lines were calculated using data points with IC50 < 50μg/ml for both bnAbs. The contingency tables on the right show the overlap in the sensitive/resistant viruses between DH1030.5 and other V3 glycan bnAbs. The overlap (accuracy) in number of mutually sensitive (sen) or resistant (res) viruses and the Fisher’s exact test P values are shown below each contingency table.
Genetic signatures were associated with the maturation of DH1030 bnAb lineage.
Next, we used LIBRA-seq (26) to identify 10 new clonally-related DH1030 Abs (D1030.7-DH1030.16) and a single cell immune profiling assay (24) to identify 46 additional clonally-related DH1030 Abs (DH1030.17-DH1030.62). Phylogenetic analysis of the first 62 DH1030 Abs isolated (traditional sorting, n=6; LIBRA-seq, n=10; single cell immune profiling, n=46) showed that they bioinformatically clustered by BCR sequence similarity into three clades; the majority of clade 1 Abs had the VH G56 signature, whereas all clade 2 Abs had the VH G56 residue, and all clade 3 Abs had the VH R56 residue (fig. S10A). Like in the human DH270 bnAb lineage (7), VH R56 was fixed in DH1030 Abs following the G56R mutation as seen in clade 3 of the DH1030 phylogram. We expressed representative mAbs from all three clades to determine the functional profiles of DH1030 Abs encoding glycine, arginine, or another residue at HCDR2 position 56. Only clade 3 DH1030 Abs neutralized heterologous tier 2 HIV-1 strains in the global panel. However, DH1030 nAbs from clades 1 and 3 neutralized heterologous tier-2 HIV-1 strain (CH848.10.17_N133DN138T) (9) with PNGS deletions in Env V1 region (V1-glycan deletions) (fig. S10B), indicative of the sensitivity of DH1030 Abs to viruses with V1-glycan deletions. Of the clade 1 and 3 nAbs, only the clade 3 nAbs were able to neutralize the CH848.10.17 strain with the V1-glycans restored (7, 9) (fig. S10C), suggesting that they had matured to accommodate V1-glycans on Env like V3-glycan bnAbs but all the clade 1 and 3 nAbs showed N332-dependent binding (fig. S10D and E).
We further analyzed heavy chain sequences for DH1030 Abs along the path to clade 3 bnAbs and found a serine-to-proline mutation at position 114 (S114P) in the HCDR3 that was present only in clade 3 bnAbs, except DH1030.4 and DH1030.5 (fig. S11A). Reverting VH P114S into DH1030.1 bnAb had minimal reduction in binding but substantial reduction in neutralization breadth (fig. S11B and C). Computational modeling of VH S114P on DH1030.1-Env complex suggested that VH P114 residue in the HCDR3 introduced a bend in the heavy chain to bring neighboring aspartic acid residue at position 113 in the HCDR3 (D113) within H-bonding distance with the N332 glycan (fig. S11D). Thus, S114P mutation in the HCDR3 may serve as a compensatory mutation to VH G56R for DH1030 maturation.
DH1030 V3-glycan bnAb lineage developed via a GC-dependent maturation pathway.
Given the maturation of HIV-1 bnAbs via GC reactions in immune tissues (14), we next sought to interrogate DH1030 GC B cells in LN and spleen using a modified Barcode Enabled Antigen Mapping (BEAM)-Ab assay (28). We used barcode-labeled antigens to identify antigen-reactive B cells from PBMCs, LNs, or spleen, although we sorted different B cell subsets in these samples based on cell surface phenotypes (fig. S12). Post-sort analysis with barcode-labeled antigens allowed deconvolution of the predicted antigen-reactive B cells among the compartments studied as previously described for BEAM-Ab assay (28). Here, we established a sequencing-based assay to assess single B cell phenotyping and BCR reactivity (PheBAR-seq).
Using PheBAR-seq, we studied eight B cell subsets from PBMCs, LNs, and spleen at week 105 post-SHIV infection, and recovered 270,746 cells with paired immunoglobulin heavy (IgH) and light (IgL) chain genes, of which were 141 new clonally-related DH1030 members (data file S2; table S4; Fig. 5A). DH1030 Abs were detected predominantly in the memory subsets of PBMCs, LNs, and spleen as well as the GC subset in the LN and spleen (Fig. 5A). Following PheBAR-seq, combined across our previous sorting strategies, we isolated a total of 203 DH1030 Abs that used macaque VH3-al encoding 17-aa long HCDR3 and paired with VK2-g gene (data file S2), and phylogenetic analyses of these Abs indicated that they clustered into different clades based on amino acid residue at VH56 position, rather than B cell compartments (fig. S13).
Figure 5. Transcriptional profiling showed cross-compartmentalization of clonally-related DH1030 B cells in peripheral blood and immune tissues.

(A) Table listing the cell surface markers for B cell subsets sorted via flow cytometry in a single experiment, and number of cells recovered for analyses of BCRs with 1:1 functional heavy-light chain pairing and GEX profiling. The number of clonally-related DH1030 BCRs based on similar VDHJH rearrangements is also shown; see data file S2 for predicted antigen reactivity of DH1030 B cells. (B) Integrated UMAP of B cells with BCRs identified in 14 unique clusters. UMAP reflects integrated LN, spleen, and peripheral blood cells that were sorted based on surface phenotype markers. (C) GEX profiling by scaled average expression for distinct lineages that make up the UMAP clusters in (B). Clusters indicative of cells in the LZ, GZ, and DZ zones of the GC, as well as of MBCs, are shown in the shaded regions on the UMAP. Each lineage was defined by canonical memory and germinal center B cell genes. (D) Integrated UMAP of B cells showing DH1030 lineage members with different genotypes based on amino acid residue at HCDR2 position 56; G (green), R (violet), or Other (blue) amino acid. Encircled regions indicate B cells in the LZ (yellow circle), GZ (gray circle), and DZ (purple circle) of the GC, as well as MBCs (green circle). (E) Frequency of DH1030 lineage members in each UMAP cluster indicated in (B).
The gene expression (GEX) profiling of the 270,746 B cells with paired IgH+IgL genes studied via PheBAR-seq was in agreement with our sort strategy for naïve, GC, or memory phenotypes from the eight cell subsets studied (fig. S14A and B). The total B cells across all three subsets clustered into 14 transcriptionally unique clusters using the Seurat R package (v5.3.0) for graph-based cell clustering, dimensionality reduction and data visualization as described (24, 28) (Fig. 5B). Clusters 1 and 2 demonstrated GEX profile consistent with memory B cells (Fig. 5C). Clusters 3, 8, 6, 13 and 9 demonstrated GEX profiles consistent with GC B cells; light zone (LZ; clusters 3 and 8), transitional or gray zone (GZ; clusters 6 and 13), and dark zone (DZ; cluster 9) GC B cell subsets (Fig. 5C). Additionally, GEX of cell cycle genes revealed distinct subsets of GC B cells in G1, S, and G2/M phases (fig. S14C and D) in agreement with previous studies that established LZ B cells in the G1 phase, transitional cells in the S phase, and DZ cells in the G2/M phases (31, 32).
Next, we interrogated the B cell subsets studied via PheBAR-seq in search of DH1030 clonal lineage members. We found DH1030 clonal lineage members primarily in the GC and memory B cell subsets (Fig. 5D). However, the highest frequency of DH1030 VH R56-contaning B cells was present in the memory B cells of LNs (cluster 1) whereas G56-containing lineage members clustered in various compartments of LN and spleen GCs (clusters 3, 6, and 9) (Fig. 5D and E). DH1030 Abs with VH G56 residue seemed to be predominantly retained in the GC; 61.54% of LN-derived GC DH1030 B cells having VH G56 residue and 23.53% of LN-derived memory DH1030 B cells having VH G56 residue (Fig. 6A). That 30.77% of LN-derived GC DH1030 B cells had the VH G56R improbable mutation and 70.59% of LN-derived memory DH1030 B cells had the VH G56R mutation suggested that DH1030 VH G56R mature lineage members were able to progress from GC to a memory phenotype (Fig. 6A). The progression of DH1030 VH R56 lineage members from GC to memory phenotype coincided with increased SHM frequencies (Fig. 6B). We functionally characterized representative DH1030 BCRs, expressed as mAbs, from memory B cells present in PBMCs, LNs, and spleen, and GC B cells present in LNs and spleen, and found that DH1030 mAbs with VH R56 residue from different B cell compartments had similar potency and breadth of HIV-1 strains (Fig. 6C).
Figure 6: DH1030 clonally-related B cells in different tissues demonstrated genetic signatures of lineage maturation.

(A) A table listing tissue origin and phenotype of DH1030 B cells bearing glycine (G), arginine (R), or other residues at HCDR2 position 56 that were studied via PheBar-seq. (B) VH SHM frequency in DH1030 B cells from different compartments; *P<0.05 by Mann-Whitney test. Here, we did not use an alpha correct method such as Bonferroni or FDR because of the exploratory nature of this hypothesis generating research. (C) Neutralization profile of representative DH1030 Abs against autologous and heterologous HIV-1 strains. Neutralization titers reported as IC50 in μg/ml. All mAbs tested had arginine at position 56 in the HCDR2, except DH1030.63^, which encoded an S56 residue. N/A, not applicable. (D) Table detailing tissue origin and phenotype of DH1030 B cells encoding S114P mutation in the HCDR3 in addition to either a glycine, arginine or other residues at HCDR2 position 56. Shown are the numbers and frequencies (%) for DH1030 BCRs with these phenotypes in different compartments. (E) Phylogenetic tree of clonally-related DH1030 VH sequences harboring G56R mutations and whether they evolved with serine (purple), proline (yellow), or other (gray) residues at position 114 in the HCDR3. DH1030 Abs indicated on the phylogram were generated as mAbs and tested for neutralization in (C), except DH1030.63 encoding S56 instead of R56 signature.
The S114P mutation in the HCDR3 of DH1030 bnAbs was an additional mutation to HCDR2 G56R that was associated with maturation for neutralization capacity (fig. S11). In the B cell subsets studied via PheBAR-seq, we found that only DH1030 VH R56-containing B cells encoded VH P114 residue and these B cells were found only in LN-derived GCs (Fig. 6D). Moreover, B cells bearing DH1030 bnAbs encoding VH R56 evolved with VH P114 transitioned from a germinal center to memory phenotype following the acquisition of this mutation, which was associated with neutralization breadth (Fig. 6E, fig. S11C). Future studies will determine if DH270-like Abs have similar compensatory mutations for maturation of neutralization potency and breadth since VH S114P mutation was not found in DH270. Overall, our findings implicate a GC-driven maturation pathway in LNs for acquisition of DH1030 key improbable mutations associated with bnAb maturation.
Viral-Env evolution mediated DH1030 bnAb lineage induction.
We used Illumina next generation deep-sequencing (NGS) to trace clonally-related DH1030 BCR sequences with similar VDHJH rearrangements in the heavy chain and VJK rearrangement in the light chain. We analyzed over 24 million BCR sequences derived from PBMC samples from weeks 12–96 post-SHIV infection and found clonal members in samples from weeks 80, 88, and 96 but not in earlier samples taken at weeks 12, 24, 64, or 72 (fig. S15A). The clonally-related DH1030 VH sequences were mutated (fig. S15B) and mainly IgG isotype (fig. S15C). From these data, we inferred the sequences of the UCA (DH1030.UCA.v2) with high confidence using the SONAR pipeline as described (20) (fig. S15D to F). To achieve this, we created RM08N021-specific germline references for the heavy and light chain variable regions using IgDiscover (33) and identified animal-specific VDHJH and VJK alleles for DH1030 bnAb UCA. As expected, SHM was acquired over time and DH1030 lineage sequences from week 80 post-SHIV infection showed SHM from the germline VDHJH allele between 0.5% and 2.1% (mean = 1.1%). This timing coincided closely with the first detection of mutations in the 324GDIR327 epitope at residue 325 (Fig. 2A to B). Thus, these data suggested that the DH1030 germline precursor was primed between week 72 and 80 post-SHIV infection, which is similar to the late priming event of the human DH270 V3-glycan bnAb lineage (7).
Next, we functionally characterized recombinant DH1030.UCA.v2 mAb to gain insights into the BG505 SHIV Env variant responsible for inducing the DH1030 lineage. Having narrowed the timing of DH1030 bnAb lineage priming to week 72–80 post SHIV infection, we examined SGS sequences near this time to identify candidate priming immunogens (Fig. 2A). We were mindful of the recent demonstration that V1 deletions in the SHIV.BG505.5MUT Env led to rapid and consistent induction of V3-glycan bnAbs in macaques (4). From an alignment of the V1 region of Env sequences cloned from SGS sequences from weeks 64 and 72 post-SHIV infection (Fig. 4A), we show that one of these sequences (w072.25) contained a 4-aa deletion in an identical position as the del4 and del8 deletions (Fig. 7A and B) as reported by Skelly et al. to be responsible for V3-glycan bnAb induction in SHIV.BG505.5MUT-infected monkeys (4). When assayed for neutralization sensitivity to the DH1030 UCA.v2 mAb, this w072.25 Env-pseudotyped virus was uniquely sensitive compared with the other forty-three RM08N021 Envs tested (Fig. 7C). Of note, this 4-aa deletion in V1 was also found in RM10N011 that also developed V3-glycan bnAbs, and in 3 other macaques (fig. S4C). In a similar fashion, the human DH270 V3-glycan bnAb UCA did not neutralize the CH848TF virus, but potently neutralized the CH848.10.17 variant with shorter V1 length that lacked glycans at residues 133 and 138 (CH848.10.17.DT) (7, 9).
Figure 7: DH1030 UCA neutralized a week 72 autologous virus from RM08N021 featuring a truncated V1 loop and reduced glycosylation.

(A) Sequence evolution of variable loop 1 (V1) in RM08N021 at weeks 64 and 72. Each row in the alignment corresponds to the V1 sequence of an isolate obtained by single-genome sequencing (SGS). Predicted N-linked glycosylation sites (PNGS) at positions 133 and 137 are annotated relative to the BG505 reference sequence. Intact PNGS are highlighted in cyan, whereas disrupted PNGS are shown in yellow. Amino acid substitutions are marked in red. (B) The infectivity-positive Env clones from panel (A) were screened at a single antibody concentration (250 μg/ml) to identify those sensitive to DH1030 UCA. The y-axis shows relative light units (RLU) of the luminescent reaction, and the x-axis lists the tested clones. Neutralization sensitivity is reflected by the reduction in RLU in wells containing DH1030 UCA (blue bars) compared to no-antibody controls (black bars). A sensitive clone is marked with a red arrow. (C) Clones from week 72, characterized by PNGS deletions, shortened V1 lengths, or specific mutations, were tested against the DH1030 UCA in a serial dilution neutralization assay starting at 250 μg/ml. The y-axis shows the percentage of infectivity relative to control wells without antibody; the x-axis represents the antibody concentration (μg/ml).
Discussion
We infected 18 RMs with a pathogenic SHIV bearing the TF Env from a prototype BG505 strain used widely in HIV-1 vaccine research to understand the molecular basis for its early strain-specific immunogenicity and how the Env evolved to elicit bnAbs. We found consistent patterns of Env evolution and immune escape in all animals in the first year of infection, and then a distinct pattern of escape focused on 324GDIR327 and N332 in 3 animals that developed V3 glycan bnAbs. Moreover, we found convergence in Env evolution with the same or similar amino acid mutations identified under selection across the macaques, which also showed convergent evolution compared with the human donor, CH848. Additionally, we isolated a large V3-glycan bnAb clonal lineage consisting of 203 members, termed the DH1030 lineage, from a representative SHIV BG505 infected RM08N021 with V3-glycan targeted plasma breadth. DH1030 Abs elicited by subtype A BG505 macaque infection demonstrated genetic, functional, and structural similarities with the human V3-glycan bnAb lineage DH270 that was elicited by a subtype C infection. Having 203 DH1030 B cell clonal lineage members facilitated extensive evaluation of the maturation pathway of DH1030 in circulating and tissue B cell compartments, and we now show that improbable mutations associated with maturation of macaque DH1030, as previously observed for human DH270, were predominantly found in memory compared to GC B cell subsets of LN and spleen. Finally, we demonstrated that an improbable mutation associated with maturation of DH1030 and DH270 V3-glycan bnAb lineages appeared to be a pivotal catalyst for lineage transition into the memory phenotype following a GC reaction. These findings implicate a trajectory for vaccines to replicate when selecting bnAb lineage members with improbable mutations that drive development towards bnAb status. In fact, the maturation pathway for DH1030 may provide a benchmark for the mechanisms of V3-glycan bnAb lineage induction in the human clinical trial that is studying DH270-like V3-glcan bnAb lineage induction (NCT05903339).
Plasma V3-glycan bnAb induction in SHIV BG505-infected macaques was associated with the evolution of Env variants with deletion of PNGS in the V1 region of Env, a concept that is currently being tested in the clinic in different Env strains to elicit V3-glycan bnAbs (34). We previously postulated that V1 PNGS-deleted Envs likely expanded the DH270 V3-glycan bnAb lineage in human HIV-1 infection (7, 9), and V1-glycan deleted Envs have been shown to be effective at isolating putative V3-glycan bnAb precursors in HIV-1 naïve humans (11, 12, 35). Enhanced neutralization of autologous and heterologous Envs with V1-glycan deletions by DH1030 mAbs, and neutralization sensitivity of DH1030.UCA.v2 mAb to an autologous Env bearing V1-glycan deletions, suggest that macaque DH1030 lineage was induced by a V1-glycan-deleted Env, consistent with recent observations by Skelly et al. in SHIV.BG505.5MUT macaque infection (4). We also identified a candidate Env priming immunogen for a macaque DH1030 V3-glycan lineage that was isolated from SHIV BG505 infected RM08N021; the Env immunogen had V1-glycan deletions, in agreement with concepts postulated for eliciting V3-glcyan bnAbs.
Previously, Wang et al. isolated and characterized a macaque V3-glycan bnAb (Ab1485) that was elicited by SHIV AD8 infection, but the authors did not study the ontogeny and maturation events of this V3-glycan bnAb lineage (36). Here, we found that macaque and human V3-glycan bnAbs used different Ig gene pairs but encoded a common motif that facilitated Ab-Env recognition in a bnAb lineage. For example, an improbable mutation in the HCDR2 of both macaque (VH G56R) and human (VH G57R) V3-glycan bnAbs was associated with the acquisition of neutralization breadth, thus demonstrating similarity in Env-specific B cell evolution in humans and SHIV-infected RMs (5, 13). Furthermore, our transcriptomic analysis of DH1030 maturation revealed that acquisition of VH G56R improbable mutation appeared to be key for both transition of DH1030 GC B cells into the memory population and driving mutations that further enhance neutralization potency and breadth such as VH S114P. These data imply that HIV-1 vaccine regimens to elicit V3-glycan bnAbs must select the appropriate mutations associated with acquisition of neutralization breadth in the BCRs of Abs at different stages of bnAb lineage development.
Our study has some limitations. In the current study, we evaluated maturation of a single bnAb lineage that was detected in a single monkey. Thus, future studies of additional SHIV-infected macaques showing a V3-glycan serum bnAb signature are warranted to further investigate conserved mechanisms of bnAb lineage maturation and viral evolution in macaque and humans. In the current study, we identified a subset of functional mutations in macaque DH1030 and human DH270 that may impact neutralization potency and breadth. However, we did not determine the mechanisms of action that support neutralization potency and breadth for all of these mutations. The role of viral Envs amplified via SGS over time in shaping the maturation of DH1030 Abs using longitudinal DH1030-like sequences amplified via Illumina NGS over time was not explored in this study. Thus, future studies evaluating functional analyses of the coevolving DH1030 Abs and viral Envs from longitudinal timepoints may provide more insights into V3-glycan bnAb lineage maturation shaped by viral-Env evolution.
Our data support other findings that variants of the BG505 Env that evolve during SHIV infection can develop features that are favorable for the induction of V3-glycan bnAbs, particularly shortening and hypoglycosylation of V1 (4). These data raise the possibility that a modified BG505 Env that mimics naturally evolved BG505 variants in infection might elicit HIV-1 Env V3-glycan targeted bnAb lineages in humans. This is consistent with recent observations that different versions of BG505 Env with V1 modifications showed promise in preclinical animal studies by inducing bnAbs (4) or bnAb precursors (37); moreover, different forms of BG505 and other strains with V1 deletions are currently being evaluated in human clinical trials for the induction of V3 glycan bnAb lineages (34). In sum, our data demonstrate that there is a common maturation pathway of human and macaque V3-glycan bnAb lineages that may be exploited for vaccine development.
Materials and Methods
Study Design
All RMs were maintained in accordance with the Association for Assessment and Accreditation of Laboratory Animals. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 2011 edition. SHIV infection of Indian RMs were performed at Bioqual Inc., Rockville, MD, as previously described (5). HIV-1 TF Envs were derived from viruses that established infection in humans, thus SHIVs bearing TF Envs, and BG505.T332N, (13) provided a model for studying HIV-1 infection as described (5). We studied SHIV BG505.T332N to determine whether the BG505 Env that is a prototypic strain widely used in HIV-1 vaccine research can elicit bnAbs as well as understand the molecular basis for its early strain-specific immunogenicity.
We studied 18 RMs; 14 RMs were inoculated with SHIV.BG505 bearing a PNGS at Env position 332 (SHIV.BG505.N332), 2 RMs with SHIV.BG505 lacking a PNGS at Env position 332 (SHIV.BG505.T332), and 2 RMs with a 50:50 mixture of these SHIVs. More animals were studied in the experimental group of interest using SHIV BG505.N332, but at least 2 in the other treatment arms that would allow for a qualitative outcome for reproducibility. Our sample size was limited by funding. Study duration was influenced by development of plasma bnAb activity, but animals that developed AIDS-like illnesses or became too ill to continue the study were euthanized. In agreement with the study objectives, we performed serology and BCR repertoire analyses on samples collected at different timepoints, including plasma, and peripheral blood and immune tissue cells. Serology is done with longitudinal plasma samples and the results inform the BCR repertoire analyses that was done on the RM08N021. BCR repertoire analyses to isolate and characterize bnAbs are performed on later timepoints of the study where plasma bnAb activity is present and more cells are available. Lineage tracing of bnAbs observed at the end of the study is performed on longitudinal cells to inform development of these B cell lineages over time.
We performed complementary assays to characterize the functional profile of Ab responses elicited by macaque SHIV infection, thus some assays were performed only once. For replicated assays, the figure legends indicate the number of times an experiment was performed, including assays for binding and neutralization. Key experiments including amplification of viral Env from plasma, and B cell isolation and lineage tracing experiments were done once using separate vials of samples that were studied at different timepoints as indicated in the manuscript. Samples were not randomized for our assays; the identity of the animals and timepoints for each sample was made available to the researchers during the experiments.
Statistical Analysis
Linear regression as implemented in SciPy (www.scipy.org) was used to compare Log10-transformed IC50 titers for DH1030.5 to other V3-glycan bnAbs using only those viruses that were neutralized by both bnAbs being compared (Fig. 4). Fisher’s exact test was used to assess the statistical significance of the overlap between sensitive and resistant viruses between DH1030.5 and other V3-glycan bnAbs. For comparisons of heavy chain SHM frequencies in DH1030 B cells from different compartments, we performed Mann-Whitney Test using GraphPad Prism v10.1.2 (Fig. 6), but did not use an alpha correct method such as Bonferroni or FDR because of the exploratory nature of this hypothesis generating research.
Supplementary Material
Supplementary materials and methods
MDAR Reproducibility Checklist
Data files S1 and S2
ACKNOWLEDGEMENTS:
The following individuals provided technical assistance: S. Holmes, R. Fenner, E. Svenson, E. Lee, R.M. Williams, M.T. Overton, S. Toure, N. Chohan, and Y. Ding. We thank M. Louder, R. Carroll, N. C. Moore, C Lin, K. McKee, and A.B. McDermott for their assistance with neutralization assessments on the 208-strain panel, and J. Baalwa, D. Ellenberger, F. Gao, B. Hahn, K. Hong, J. Kim, F. McCutchan, D. Montefiori, L. Morris, E. Sanders-Buell, G. Shaw, R. Swanstrom, M. Thomson, S. Tovanabutra, C. Williamson, and L. Zhang for contributing the HIV-1 envelope plasmids used in this neutralization panel. Cryo-EM data were collected at the Shared Materials Instrumentation Facility at Duke University and National Center for CryoEM Access and Training and the Simons Electron Microscopy Center located at the New York Structural Biology Center.
Funding.:
P01-AI131251 (G.M.S); UM1-AI100645 and UM1-AI44371 (B.F.H); R01-AI145687 and Translating Duke Health Initiative (P.A.); R37-AI140897, UM1-AI169633 and Duke School of Medicine Whitehead Scholarship (W.B.W); R01-AI120801 (K.O.S.); Duke CFAR. This study used the computational resources offered by Duke Research Computing (http://rc.duke.edu). CryoEM data generated for this study was supported by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539) and by grants from the Simons Foundation (SF349247).
Footnotes
Competing interests. The authors have no competing interests.
Data, code, and materials availability.
All data associated with this study are in the paper or supplementary materials. DH1030 BCR genes are provided in data file S2. Cryo-EM maps and models of DH1030.1 Fab bound to BG505 Env were deposited to the EMDB and PDB with accession numbers EMD-27628 and 8DP1, respectively. Cryo-EM maps and models of DH1030.1 Fab bound to CH848 Env were deposited to the EMDB and PDB with accession numbers EMD-27624 and 8DOW, respectively. The crystal structure of the DH1030.1 Fab was deposited to the PDB under accession code 8DKF. Custom scripts used in this manuscript for BCR and transcriptome sequencing analyses have been deposited to Zenodo at https://doi.org/10.5281/zenodo.18189698 and to GitHub at https://github.com/WieheLab/DH1030_RM08N021_manuscript. The transcriptome sequencing data were deposited in NCBI Sequence Read Archive under Bioproject accession number PRJNA1400054 and BioSample accession numbers SAMN54527203, SAMN54527204, and SAMN54527205. The research materials such as plasmids bearing Ab or Env genes for protein production or plasmids for SHIV production used in this study are available from Duke University and University of Pennsylvania upon request to the corresponding authors and subsequent execution of an appropriate materials transfer agreement, given the use of proprietary constructs for expression of these products. All other materials used or generated in this study are commercially available or will be supplied upon reasonable request.
REFERENCES:
- 1.Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20: 796–803 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR, Investigators PGP. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998–10009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Skelly A, Gristick H, Li H, Gavor E, Connell A, Kreider E, Marchitto L, Hogarty M, Newby M, Allen J, Liu W, West A Jr., Ayyanathan K, Campion M, Winters K, Gordon C, Osbaldeston R, Akeley M, Li Y, Singh A, Cruickshank K, Park Y, Zhao C, Li X, Amereh K, Van Itallie E, Carey J, Albertus A, DeLaitsch A, Keeffe J, Lituchy M, Walsh A, Morris D, Habib R, Bibollet-Ruche F, Mishra N, Avillion G, Koranda N, Plante S, Martella C, Lora J, Wang E, Lewis M, Martin M, Nussenzweig M, Seaman M, Irvine D, Wiehe K, Haynes B, Wagh K, Korber B, Andrabi R, Crispin M, Weissman D, Bjorkman P, Hahn B, Shaw G. 2025. Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design. bioRxiv preprint [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, Wang S, Lee FH, Rando J, Bonsignori M, Hwang KK, Saunders KO, Wiehe K, Moody MA, Hraber PT, Wagh K, Giorgi EE, Russell RM, Bibollet-Ruche F, Liu W, Connell J, Smith AG, DeVoto J, Murphy AI, Smith J, Ding W, Zhao C, Chohan N, Okumura M, Rosario C, Ding Y, Lindemuth E, Bauer AM, Bar KJ, Ambrozak D, Chao CW, Chuang GY, Geng H, Lin BC, Louder MK, Nguyen R, Zhang B, Lewis MG, Raymond D, Doria-Rose NA, Schramm CA, Douek DC, Roederer M, Kepler TB, Kelsoe G, Mascola JR, Kwong PD, Korber BT, Harrison SC, Haynes BF, Hahn BH, Shaw GM. 2020. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wang Z, Merkenschlager J, Chen ST, Oliveira TY, Ramos V, Gordon KM, Yao KH, Jankovic M, Nussenzweig M, Escolano A. 2020. Isolation of single HIV-1 Envelope specific B cells and antibody cloning from immunized rhesus macaques. J Immunol Methods 478: 112734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hwang KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, Cohen MS, Hraber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF. 2017. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med 9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wiehe K, Bradley T, Meyerhoff RR, Hart C, Williams WB, Easterhoff D, Faison WJ, Kepler TB, Saunders KO, Alam SM, Bonsignori M, Haynes BF. 2018. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host Microbe 23: 759–65.e6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, Hsu AL, Borgnia MJ, Chen H, Lu X, Wu NR, Watts B, Jiang C, Easterhoff D, Cheng HL, McGovern K, Waddicor P, Chapdelaine-Williams A, Eaton A, Zhang J, Rountree W, Verkoczy L, Tomai M, Lewis MG, Desaire HR, Edwards RJ, Cain DW, Bonsignori M, Montefiori D, Alt FW, Haynes BF. 2019. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science 366 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wiehe K, Saunders KO, Stalls V, Cain DW, Venkatayogi S, Martin Beem JS, Berry M, Evangelous T, Henderson R, Hora B, Xia SM, Jiang C, Newman A, Bowman C, Lu X, Bryan ME, Bal J, Sanzone A, Chen H, Eaton A, Tomai MA, Fox CB, Tam YK, Barbosa C, Bonsignori M, Muramatsu H, Alam SM, Montefiori DC, Williams WB, Pardi N, Tian M, Weissman D, Alt FW, Acharya P, Haynes BF. 2024. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction. Cell Host Microbe 32: 693–709.e7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, Torres JL, Kalyuzhniy O, Melzi E, Kulp DW, Raemisch S, Hu X, Bernard SM, Georgeson E, Phelps N, Adachi Y, Kubitz M, Landais E, Umotoy J, Robinson A, Briney B, Wilson IA, Burton DR, Ward AB, Crotty S, Batista FD, Schief WR. 2019. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science 366 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC. 2019. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature 570: 468–73 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM. 2016. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A 113: E3413–22 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Havenar-Daughton C, Lee JH, Crotty S. 2017. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol Rev 275: 49–61 [DOI] [PubMed] [Google Scholar]
- 15.Nakagawa R, Calado DP. 2021. Positive Selection in the Light Zone of Germinal Centers. Front Immunol 12: 661678. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.De Silva NS, Klein U. 2015. Dynamics of B cells in germinal centres. Nat Rev Immunol 15: 137–48 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.van Schooten J, van Haaren MM, Li H, McCoy LE, Havenar-Daughton C, Cottrell CA, Burger JA, van der Woude P, Helgers LC, Tomris I, Labranche CC, Montefiori DC, Ward AB, Burton DR, Moore JP, Sanders RW, Crotty S, Shaw GM, van Gils MJ. 2021. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS Pathog 17: e1009736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307–12 [DOI] [PubMed] [Google Scholar]
- 20.Habib R, Roark RS, Li H, Connell AJ, Hogarty MP, Wagh K, Wang S, Marchitto L, Skelly AN, Carey JW, Sowers KJ, Ayyanathan K, Plante SJ, Bibollet-Ruche F, Park Y, Agostino CJ, Singh A, Martella CL, Lewis E, Rando JM, Chohan N, Lora J, Ding W, Campion MS, Zhao C, Liu W, Li Y, Li X, Liang B, Chowdhury RR, Amereh K, Van Itallie E, Sheng Z, Ghosh AR, Bar KJ, Williams WB, Wiehe K, Saunders KO, Edwards RJ, Cain DW, Lewis MG, Batista FD, Burton DR, Andrabi R, Kulp DW, Haynes BF, Korber B, Shapiro L, Kwong PD, Hahn BH, Shaw GM. 2026. Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development. Sci Immunol 11: eadz3933. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM, Shaw GM, Hahn BH. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: 3952–70 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hraber P, Korber B, Wagh K, Giorgi EE, Bhattacharya T, Gnanakaran S, Lapedes AS, Learn GH, Kreider EF, Li Y, Shaw GM, Hahn BH, Montefiori DC, Alam SM, Bonsignori M, Moody MA, Liao HX, Gao F, Haynes BF. 2015. Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses 7: 5443–75 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP. 2018. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS Pathog 14: e1006913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Williams WB, Meyerhoff RR, Edwards RJ, Li H, Manne K, Nicely NI, Henderson R, Zhou Y, Janowska K, Mansouri K, Gobeil S, Evangelous T, Hora B, Berry M, Abuahmad AY, Sprenz J, Deyton M, Stalls V, Kopp M, Hsu AL, Borgnia MJ, Stewart-Jones GBE, Lee MS, Bronkema N, Moody MA, Wiehe K, Bradley T, Alam SM, Parks RJ, Foulger A, Oguin T, Sempowski GD, Bonsignori M, LaBranche CC, Montefiori DC, Seaman M, Santra S, Perfect J, Francica JR, Lynn GM, Aussedat B, Walkowicz WE, Laga R, Kelsoe G, Saunders KO, Fera D, Kwong PD, Seder RA, Bartesaghi A, Shaw GM, Acharya P, Haynes BF. 2021. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fan Q, Nelson CS, Bialas KM, Chiuppesi F, Amos J, Gurley TC, Marshall DJ, Eudailey J, Heimsath H, Himes J, Deshpande A, Walter MR, Wussow F, Diamond DJ, Barry PA, Moody MA, Kaur A, Permar SR. 2017. Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission. Clin Vaccine Immunol 24 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, Richardson S, Oosthuysen C, Raju N, Ronsard L, Kanekiyo M, Qin JS, Kramer KJ, Greenplate AR, McDonnell WJ, Graham BS, Connors M, Lingwood D, Acharya P, Morris L, Georgiev IS. 2019. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell 179: 1636–46.e15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88: 2489–507 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Holmes S, Li H, Shen X, Martin M, Tuck R, Chen Y, Giorgi EE, Kirshner HF, Berry M, Van Italie E, Venkatayogi S, Martin Beem JS, Edwards RJ, Mansouri K, Singh A, Kuykendall C, Gurley T, Anthony Moody M, DeNayer N, Demarco T, Denny TN, Wang Y, Evangelous TD, Clinton JT, Hora B, Wagh K, Seaman MS, Saunders KO, Solomotis N, Misamore J, Lewis MG, Wiehe K, Montefiori DC, Shaw GM, Williams WB. 2024. Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques. Nat Commun 15: 10302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Syeda MZ, Hong T, Huang C, Huang W, Mu Q. 2024. B cell memory: from generation to reactivation: a multipronged defense wall against pathogens. Cell Death Discov 10: 117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Knox JJ, Buggert M, Kardava L, Seaton KE, Eller MA, Canaday DH, Robb ML, Ostrowski MA, Deeks SG, Slifka MK, Tomaras GD, Moir S, Moody MA, Betts MR. 2017. T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight 2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Pae J, Ersching J, Castro TBR, Schips M, Mesin L, Allon SJ, Ordovas-Montanes J, Mlynarczyk C, Melnick A, Efeyan A, Shalek AK, Meyer-Hermann M, Victora GD. 2021. Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. J Exp Med 218 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kennedy DE, Okoreeh MK, Maienschein-Cline M, Ai J, Veselits M, McLean KC, Dhungana Y, Wang H, Peng J, Chi H, Mandal M, Clark MR. 2020. Novel specialized cell state and spatial compartments within the germinal center. Nat Immunol 21: 660–70 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Corcoran MM, Phad GE, Vázquez Bernat, Stahl-Hennig C, Sumida N, Persson MA, Martin M, Karlsson Hedestam GB. 2016. Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity. Nat Commun 7: 13642. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Haynes BF, Saunders KO, Hahn BH, Wiehe K, Baden LR, Shaw GM. 2025. Status of HIV vaccine development: progress and promise. J Int AIDS Soc 28: e26489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. 2016. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45: 483–96 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Wang Z, Barnes CO, Gautam R, Cetrulo Lorenzi JC, Mayer CT, Oliveira TY, Ramos V, Cipolla M, Gordon KM, Gristick HB, West AP, Nishimura Y, Raina H, Seaman MS, Gazumyan A, Martin M, Bjorkman PJ, Nussenzweig MC, Escolano A. 2020. A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. Elife 9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Nelson AN, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, Sewall LM, Milligan E, Davis D, Cross KA, Chen Y, van Schooten J, Eudailey J, Isaac J, Memon S, Weinbaum C, Gao H, Stanfield-Oakley S, Byrd A, Chutkan S, Berendam S, Cronin K, Yasmeen A, Alam S, LaBranche CC, Rogers K, Shirreff L, Cupo A, Derking R, Villinger F, Klasse PJ, Ferrari G, Williams WB, Hudgens MG, Ward AB, Montefiori DC, Van Rompay KKA, Wiehe K, Moore JP, Sanders RW, De Paris K, Permar SR. 2024. Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques. Sci Immunol 9: eadm7097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Saunders KO, Edwards RJ, Tilahun K, Manne K, Lu X, Cain DW, Wiehe K, Williams WB, Mansouri K, Hernandez GE, Sutherland L, Scearce R, Parks R, Barr M, DeMarco T, Eater CM, Eaton A, Morton G, Mildenberg B, Wang Y, Rountree RW, Tomai MA, Fox CB, Moody MA, Alam SM, Santra S, Lewis MG, Denny TN, Shaw GM, Montefiori DC, Acharya P, Haynes BF. 2022. Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. Sci Transl Med 14: eabo5598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Kumar S, Moral-Sánchez ID, Singh S, Newby ML, Allen JD, Bijl TPL, Vaghani Y, Jing L, Lodha R, Ortlund EA, Crispin M, Patel A, Sanders RW, Luthra K. 2025. The Design and Immunogenicity of an HIV-1 Clade C Pediatric Envelope Glycoprotein Stabilized by Multiple Platforms. Vaccines (Basel) 13 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Rognes T, Flouri T, Nichols B, Quince C, Mahé F. 2016. VSEARCH: a versatile open source tool for metagenomics. PeerJ 4: e2584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.McDavid A, Finak G, Chattopadyay PK, Dominguez M, Lamoreaux L, Ma SS, Roederer M, Gottardo R. 2013. Data exploration, quality control and testing in single-cell qPCR-based gene expression experiments. Bioinformatics 29: 461–7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307–26 [DOI] [PubMed] [Google Scholar]
- 43.McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40: 658–74 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213–21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Liebschner D, Afonine PV, Baker ML, Bunkóczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ, Moriarty NW, Oeffner RD, Poon BK, Prisant MG, Read RJ, Richardson JS, Richardson DC, Sammito MD, Sobolev OV, Stockwell DH, Terwilliger TC, Urzhumtsev AG, Videau LL, Williams CJ, Adams PD. 2019. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol 75: 861–77 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, Adams PD. 2018. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol 74: 531–44 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data associated with this study are in the paper or supplementary materials. DH1030 BCR genes are provided in data file S2. Cryo-EM maps and models of DH1030.1 Fab bound to BG505 Env were deposited to the EMDB and PDB with accession numbers EMD-27628 and 8DP1, respectively. Cryo-EM maps and models of DH1030.1 Fab bound to CH848 Env were deposited to the EMDB and PDB with accession numbers EMD-27624 and 8DOW, respectively. The crystal structure of the DH1030.1 Fab was deposited to the PDB under accession code 8DKF. Custom scripts used in this manuscript for BCR and transcriptome sequencing analyses have been deposited to Zenodo at https://doi.org/10.5281/zenodo.18189698 and to GitHub at https://github.com/WieheLab/DH1030_RM08N021_manuscript. The transcriptome sequencing data were deposited in NCBI Sequence Read Archive under Bioproject accession number PRJNA1400054 and BioSample accession numbers SAMN54527203, SAMN54527204, and SAMN54527205. The research materials such as plasmids bearing Ab or Env genes for protein production or plasmids for SHIV production used in this study are available from Duke University and University of Pennsylvania upon request to the corresponding authors and subsequent execution of an appropriate materials transfer agreement, given the use of proprietary constructs for expression of these products. All other materials used or generated in this study are commercially available or will be supplied upon reasonable request.
